MindMed stock has spiked higher by over 30%, on big volume. New investor focus on the deepest clinical research program in the industry.
MindMed stock has spiked higher by over 30%, on big volume. New investor focus on the deepest clinical research program in the industry.
Psychedelic stock warrants that are currently out of the money COULD produce big returns for investors.
The road to psychedelic drug success leads through functional mushrooms.
Canada stands out as the premier destination for psychedelic drug companies.
Compass has boosted its IPO financing by roughly 20% AND increased the unit price -- signalling strong interest in the psychedelic space.
A $225 billion treatment market is badly in need of new therapies. Here is the roadmap for investors to capitalize on this opportunity.
Functional mushrooms are a large-and-growing health supplements market with synergies to psychedelics operations.
Spravato has not been the "game-changer" for treating depression that it was touted as being. The market remains wide open for psilocybin (and other psychedelics).
ATAI Life Sciences is looking more and more like the driving force in the psychedelic drug industry.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now